017180 — Myungmoon Pharm Co Share Price
Last trade - 00:00- KR₩69bn
- KR₩157bn
- KR₩170bn
- 18
- 64
- 10
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.83 | ||
| Price to Tang. Book | 0.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.41 | ||
| EV to EBITDA | 35.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.19% | ||
| Return on Equity | -5.23% | ||
| Operating Margin | 0.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 149,346.28 | 127,852.86 | 144,759.9 | 152,134.94 | 169,567.37 | n/a | n/a | 2.83% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MyungMoon Pharm. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The Company is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.
Directors
- Cheol Han Bae CCE (65)
- Chun Sik Park CCE (55)
- Jae Geon Hah VPR (52)
- Sang Jin Bae OTH (61)
- Gi Beom Kim OTH (55)
- Wu Yeong Lee OTH (54)
- Yeong Mi Lee OTH (53)
- Chang Hun Shin OTH (51)
- Yong Gyeong Sung OTH (49)
- Yong Jin Jung NID (48)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 1st, 1983
- Public Since
- July 10th, 2008
- No. of Shareholders
- 24,190
- No. of Employees
- 481
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 33,527,198
- Address
- 26, Jeyakgongdan 2-gil, Hyangnam-eup, HWASEONG, 18622
- Web
- http://www.mmpharm.co.kr/
- Phone
- +82 313504000
- Auditors
- KPMG Samjong Accounting Corp
Upcoming Events for 017180
Similar to 017180
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 19:15 UTC, shares in Myungmoon Pharm Co are trading at KR₩2,055. This share price information is delayed by 15 minutes.
Shares in Myungmoon Pharm Co last closed at KR₩2,055 and the price had moved by -18.66% over the past 365 days. In terms of relative price strength the Myungmoon Pharm Co share price has underperformed the FTSE Developed Asia Pacific Index by -18.59% over the past year.
There is no consensus recommendation for this security.
Myungmoon Pharm Co does not currently pay a dividend.
Myungmoon Pharm Co does not currently pay a dividend.
Myungmoon Pharm Co does not currently pay a dividend.
To buy shares in Myungmoon Pharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩2,055, shares in Myungmoon Pharm Co had a market capitalisation of KR₩69bn.
Here are the trading details for Myungmoon Pharm Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 017180
Based on an overall assessment of its quality, value and momentum Myungmoon Pharm Co is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Myungmoon Pharm Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -17.63%.
As of the last closing price of KR₩2,055, shares in Myungmoon Pharm Co were trading -8.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Myungmoon Pharm Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩2,055.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Myungmoon Pharm Co's management team is headed by:
- Cheol Han Bae - CCE
- Chun Sik Park - CCE
- Jae Geon Hah - VPR
- Sang Jin Bae - OTH
- Gi Beom Kim - OTH
- Wu Yeong Lee - OTH
- Yeong Mi Lee - OTH
- Chang Hun Shin - OTH
- Yong Gyeong Sung - OTH
- Yong Jin Jung - NID